SCHEMBL6079952

SCHEMBL6079952

COC(=O)c1cc(O)c2cc(CCCO)cc(N)c2n1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP4A11 Q02928 5/20 0.41
NQO2 P16083 4/20 0.39
CYP4F2 P78329 4/20 0.37
TNKS2 Q9H2K2 1/20 0.35
ALDH1A1 P00352 3/20 0.34
GAA P10253 2/20 0.34
GFER P55789 1/20 0.34
LCK P06239 1/20 0.34
TLR7 Q9NYK1 3/20 0.33
KDM4E B2RXH2 2/20 0.33
MAPT P10636 2/20 0.33
PKM P14618 1/20 0.33
HPGD P15428 1/20 0.32
ALOX15 P16050 1/20 0.32
TSHR P16473 1/20 0.32
HSD17B10 Q99714 1/20 0.32
TLR8 Q9NR97 1/20 0.32
PTGER4 P35408 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6080865 0.89 CYP4A11 (0.43) CYP4A11NQO2CYP4F2TNKS2LCK
SCHEMBL6080727 0.85 IGFBP5 (0.36) TNKS2KDM4EMAPTALOX15TSHR
SCHEMBL6080238 0.85 PLA2G2A (0.42) NQO2ALDH1A1KDM4EMAPTPKM
SCHEMBL6080853 0.85 NQO2 (0.35) NQO2ALDH1A1GAAGFERLCK
SCHEMBL6080014 0.82 CA1 (0.38) NQO2GAA
SCHEMBL6080283 0.80 EGFR (0.42) NQO2ALDH1A1KDM4EHPGDTSHR
SCHEMBL6080256 0.79 NQO2 (0.45) NQO2ALDH1A1GAALCKKDM4E
SCHEMBL6079518 0.79 NQO2 (0.45) NQO2ALDH1A1GAAGFERLCK
SCHEMBL6081104 0.78 NQO2 (0.45) NQO2ALDH1A1GAAGFERLCK
SCHEMBL21044485 0.77 CYP4A11 (0.56) CYP4A11NQO2CYP4F2TNKS2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US claimed
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NQO1, NQO2, RECQL CYP4A11 539/4885NQO2 2/4885CYP4F2 300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.